Common flaws in oncology NDAs that fail to receive approval could have been addressed by the pre-submission meetings encouraged under FDA’s program to increase review efficiency, an agency analysis of failed new molecular entity oncology NMEs concluded.
Many of the failed applications tried to assert a drug benefit without well-controlled trials showing a statistically significant effect on...